Open Access
| Issue |
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
|
|
|---|---|---|
| Page(s) | 1005 - 1007 | |
| Section | Les anticorps dans les maladies autres qu’oncologiques | |
| DOI | https://doi.org/10.1051/medsci/2019199 | |
| Published online | 06 January 2020 | |
- Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354 : 899–910. [Google Scholar]
- Tintore M, Vidal-Jordana A, Sastre-Garriga J . Treatment of multiple sclerosis: success from bench to bedside. Nat Rev Neurol 2019 ; 15 : 53–8. [CrossRef] [PubMed] [Google Scholar]
- Schilling S, Rahfeld JU, Lues I, et al. Passive Aβ immunotherapy: current achievements and future perspectives. Molecules 2018 ; 23. [Google Scholar]
- Braak H, Braak E . Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991 ; 82 : 239–59. [CrossRef] [PubMed] [Google Scholar]
- Gerson J, Kayed R . Therapeutic approaches targeting pathological tau aggregates. Curr Pharm Des 2016 ; 22 : 4028–39. [CrossRef] [PubMed] [Google Scholar]
- Pradat PF, Bruneteau G, Gonzalez de Aguilar JL, et al. Muscle Nogo-A expression is a prognostic marker in lower motor neuron syndromes. Ann Neurol 2007 ; 62 : 15–20. [CrossRef] [PubMed] [Google Scholar]
- Meininger V, Genge A, van den Berg LH, et al. NOG112264 study group . Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2017 ; 16 : 208–16. [CrossRef] [PubMed] [Google Scholar]
- Ineichen BV, Plattner PS, Good N, et al. Nogo-A antibodies for progressive multiple sclerosis. CNS Drugs 2017 ; 31 : 187–98. [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.